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Prenatal/obstetric complications are implicated in schizophrenia susceptibility. Some complications may arise from maternal-
fetal genotype incompatibility, a term used to describe maternal-fetal genotype combinations that produce an adverse prenatal
environment. A review of maternal-fetal genotype incompatibility studies suggests that schizophrenia susceptibility is increased
by maternal-fetal genotype combinations at the RHD and HLA-B loci. Maternal-fetal genotype combinations at these loci are
hypothesized to have an eﬀect on the maternal immune system during pregnancy which can aﬀect fetal neurodevelopment
and increase schizophrenia susceptibility. This article reviews maternal-fetal genotype incompatibility studies and schizophrenia
and discusses the hypothesized biological role of these “incompatibility genes”. It concludes that research is needed to further
elucidate the role of RHD and HLA-B maternal-fetal genotype incompatibility in schizophrenia and to identify other genes
that produce an adverse prenatal environment through a maternal-fetal genotype incompatibility mechanism. Eﬀorts to develop
more sophisticated study designs and data analysis techniques for modeling maternal-fetal genotype incompatibility eﬀects are
warranted.
1.Introduction
Schizophrenia has long been regarded a signiﬁcant public
health issue. This condition, which is estimated to aﬀect
more than 2 million persons in the U.S. alone [1], has
increased mortality and morbidity compared to the general
population [2, 3]. Individuals with schizophrenia typically
suﬀer from a combination of debilitating symptoms includ-
ing hallucinations and delusions and treatment-resistant
symptoms, such as social withdrawal [4]. The disease
aﬀects males and females, although there is evidence to
support a number of sex diﬀerences in the characteristics
of schizophrenia. Compared to females, males may be more
likely to develop schizophrenia with ∼1.4 : 1 ratio [5, 6],
have an earlier age at onset [6–8], poorer premorbid social
and intellectual functioning, poorer course and medication
response, greater structural brain abnormalities [9], more
negative, symptoms and fewer aﬀective symptoms [10].
Twin, family, and adoption studies together suggest that
schizophrenia is a complex disorder involving both genes
and environment [11, 12]. Further, the evidence suggesting
that schizophrenia arises from a process involving prenatal
environmental conditions is compelling [13–21]. Numerous
case-control studies have demonstrated that individuals
with schizophrenia are more likely to have been exposed
to prenatal/obstetric complications than their unaﬀected
siblings, normal controls, or psychiatric controls [22], and a
meta-analysis of twelve twin studies [11] demonstrated that
a nontrivial proportion of liability to schizophrenia can be
accounted for by a common or shared environmental eﬀect
(11%; 95% CI 3%–19%). Because the environments of twins
are most similar in utero, the role of common environment
eﬀects on liability for schizophrenia would most likely
occur very early in life. Suspected fetal environmental risks
include exposure to maternal stress [23], inﬂuenza [24–26],
infection [27], famine or prenatal nutritional deﬁciency
[16, 28–31], and obstetric complications [14, 15, 18, 19, 32].
Several reviews [8, 21, 33], including a meta analysis [19],
support the involvement of (i) pregnancy complications
such as Rhesus D incompatibility and pre-eclampsia,2 Journal of Biomedicine and Biotechnology
(ii) abnormal fetal growth and development, and (iii)
delivery complications that produce fetal hypoxia as risk
factors and suggest that obstetric complications contribute
approximately a 2-fold increased risk for schizophrenia.
Prenatal/obstetric complications are believed to disrupt nor-
mal fetal neurodevelopment and their involvement in schi-
zophrenia susceptibility is consistent with the neurode-
velopmental hypothesis of schizophrenia. This hypothesis
posits that brain development is disrupted early in life
and that subsequent maturational events in combination
with other environmental factors leads to the emergence of
psychosis during adulthood [34–36].
Support for the important role of prenatal/obstetric
complications in schizophrenia also comes from neuroimag-
ing studies. As an example, there is evidence that fetal
hypoxia has a diﬀerential eﬀect on the hippocampus of
schizophrenics and their ﬁrst degree relatives, suggesting
that this temporal lobe region may be sensitive to prenatal
environmentalconditions[37–39].Furthermore,anatomical
deﬁcits in the medial temporal lobe structures are more
severe among patients with schizophrenia who have a
history of hypoxia-associated obstetric complications [40].
Hence, not only do these studies suggest that factors that
produce prenatal/obstetric hypoxia have an eﬀect on the
medial temporal lobe structure, but that genetic liability to
schizophrenia also plays a role in predisposing an individual
to schizophrenia. This evidence has produced a variety
of hypotheses regarding how genetic and environmental
inﬂuences aggregate to increase susceptibility to schizophre-
nia, with gene-environment interaction, gene-environment
covariation, or direct environmental eﬀects, that is, pheno-
copy model, as (potentially overlapping) models [41]. To
date, there is very little evidence to support a phenocopy
model or a gene-environment covariation model to explain
the role of prenatal/obstetric complications in schizophre-
nia, although additional investigation of these models is
warranted [41]. In contrast, evidence that prenatal/obstetric
complications increase risk for schizophrenia through a
gene-environment interaction model is accumulating. In
addition to the studies cited earlier [37–40], a recent
study found that risk of schizophrenia was greatest among
individuals at highest familial liability who were exposed to
maternal infection (consistent with an interaction model)
[27]. As another example, signiﬁcant interaction between
suspected hypoxia-regulated/vascular-expression genes and
serious obstetric complications (predominantly hypoxia)
was found to inﬂuence risk for schizophrenia [42].
Although the causes for prenatal complications are
quite heterogeneous, their diversity does not exclude a
ﬁnal common pathway and there is increasing discussion
that the common pathway involves both the immune and
vascular systems in the pathogenesis of schizophrenia [43,
44]. In an excellent review of this theory of schizophre-
nia, Hanson and Gottesman [43] describe a process in
which ubiquitous environmental factors that normally trig-
ger genetically-inﬂuenced inﬂammatory response (infec-
tion, trauma, hypoxia) in individuals will trigger abnor-
mal inﬂammatory processes in individuals with particu-
lar genotypes at these inﬂammatory response loci which
results in damage to the microvascular system in the brain.
This vascular-inﬂammatory theory not only accommodates
the diversity of prenatal complications associated with
schizophrenia, but also speciﬁes an interaction between
genes and environment. The latter point helps to explain
why most people who experience prenatal/obstetric compli-
cationsdonoteventuallydevelopschizophrenia[19,21],and
has received empirical support through the increasing num-
ber of studies demonstrating gene-environment interactions
inschizophrenia[27,37–40,42],particularlytherecentstudy
that identiﬁed an interaction between serious obstetric com-
plications and hypoxia-regulated/vascular-expression genes
[42].
Not surprisingly, there remains considerable interest in
identifying fetal environmental risk factors and elucidat-
ing their role in schizophrenia. However, in addition to
their heterogeneity, prenatal/obstetric complications can be
diﬃcult to document reliably through medical records or
maternal recall, making it diﬃcult to test the role of envi-
ronmental insults in the pathogenesis of schizophrenia. Of
interest, there is some evidence that prenatal complications
that increase susceptibility to schizophrenia cluster within
schizophrenia families [45], which raises the possibility that
some of these complications may have a genetic basis and
that these risk genes and hence, adverse prenatal environ-
ment, can be measured directly through genetic analyses
rather than through medical records or maternal recall.
A beneﬁt of direct measurement of the adverse prenatal
environment through genetic analysis is that it can facilitate
hypothesis testing regarding the role of prenatal/obstetric
complications in the pathogenesis of schizophrenia.
Maternal-fetal genotype incompatibility, ﬁrst described
by Palmer et al. [47] to describe a mechanism that confers
riskforschizophrenia throughmaternal-fetalgenotypecom-
binations which produce a maternal immunological reaction
that creates an adverse prenatal environment, is an example
of a prenatal/obstetric complication with a genetic basis. As
will be described, maternal-fetal genotype incompatibility
can occur when maternal and fetal genotypes diﬀer from
one another, or when maternal and fetal genotypes are
too similar to each other. “Incompatibility genes” for each
of these scenarios have been implicated as risk factors
for schizophrenia and are reviewed below. Importantly,
maternal-fetal genotype incompatibility is explicitly genetic
in nature and so has the potential to be measured directly
through genetic analyses even years after the adverse prenatal
event has occurred.
2.RHD Maternal-FetalGenotype
Incompatibility as a Risk Factor for
Schizophrenia: When Maternaland Fetal
GenotypesDiffer
The teratogenic antibody hypothesis [46] posits that a
pregnant female can develop antibodies in response to some
antibody producing stimulus (e.g., contact with paternal
antigens) that can interfere with normal fetal neurodevel-
opment. One general mechanism that is consistent withJournal of Biomedicine and Biotechnology 3
the teratogenic antibody hypothesis involves maternal-fetal
genotype combinations that adversely aﬀect the developing
fetus by inducing a maternal immunological attack. This
mechanism is a form of maternal-fetal genotype incompat-
ibility [47], where the development of maternal antibodies
can be the result of a mother’s genotype that is diﬀerent from
the fetus’ genotype.
In some cases, a maternal immunological reaction can
lead to hypoxic ischemia, a condition found to be associated
with schizophrenia [17, 18], and hypothesized to trigger
abnormal inﬂammatory processes in individuals with vul-
nerable genotypes at inﬂammatory response loci resulting
in damage to the micro-vascular system in the brain and
increasing risk for schizophrenia [43]. Conditions that can
produce fetal or neonatal hypoxia include maternal-fetal
genotype incompatibilities at genes that produce red blood
c e l la n t i g e n s ,s u c ha st h eRHD locus.
The RHD gene produces a red blood cell antigen called
the Rhesus D factor. An individual who is determined to
be Rhesus D positive has red blood cells (RBCs) with this
antigen, while someone classiﬁed as Rhesus D negative lacks
this antigen [48]. Individuals who are Rhesus D positive
are either homozygous or heterozygous for an allele that
produces the antigen (referred to here as D/D or D/d).
Individuals who are Rhesus D negative are homozygous for
a null allele (d/d). In Caucasian populations, approximately
85% of individuals are Rhesus D positive [48].
RHD maternal-fetal genotype incompatibility during
pregnancy occurs when a pregnant woman is Rhesus D
negative (d/d) and her fetus is Rhesus D positive (D/d).
Because the RBCs of a Rhesus D negative pregnant female
do not possess the Rhesus D antigen, maternal anti-D (IgG)
antibodies are created in response to detection of fetal RBCs
in the maternal blood stream [48]. These antibodies destroy
the fetal RBCs in the maternal blood stream, cross the
placenta, and destroy fetal RBCs. Because RBCs carry oxygen
throughout the fetus’ body, including the brain, an attack on
the fetal RBCs increases risk for fetal hypoxia which could
aﬀect developing tissue, including brain tissue. A byproduct
of the destruction of RBCs is bilirubin; thus hyperbilirubine-
mia, or jaundice can occur, as well as kernicterus, which is
depositionofbilirubininthebrain[49].Bilirubinisaknown
neurotoxin [50, 51] to which undiﬀerentiated glial cells are
sensitive [52, 53], and glial cell abnormalities also have been
associated with schizophrenia [54, 55].
An infant is said to have Rhesus hemolytic disease
of the newborn when clinical complications arise due to
the RHD maternal-fetal genotype incompatibility. Because
maternal sensitization usually does not occur until delivery
of the ﬁrst RHD incompatible pregnancy, it is not until
second- and later-incompatible pregnancies that risk for a
maternal immune attack becomes appreciable [48]. Around
1970 prophylaxis against maternal isoimmunization became
available [56], which has made a dramatic impact on the
morbidity and mortality associated with RHD maternal-
fetal genotype incompatibility. However, even in an era of
prophylaxis, there continue to be cases of Rhesus hemolytic
disease of the newborn, either due to lack of prophylaxis use
[56,57],orbecauseitsuseisnot100%eﬀectiveatpreventing
maternal sensitization [58, 59].
Evidence to support involvement of RHD maternal-fetal
genotype incompatibility in schizophrenia comes from both
nongenetic and genetic studies performed on samples in
which individuals with schizophrenia predominantly were
born prior to 1970 [15, 19, 47, 60–66] and reviewed in [67].
The nongenetic studies are based on serotype data (Rhesus
D negative, Rhesus D positive) or evidence of hemolytic
disease of the newborn in mother-child pairs [19, 32, 60,
61, 63, 64, 66], while the genetic studies are based on
genotype data (D/D, D/d, d/d) and nuclear families [47,
65, 67]. Collectively, these studies have provided evidence
that RHD maternal-fetal genotype incompatibility is a risk
factor for schizophrenia with relative risk ranging from 1.4
[32]t o2 . 2 6[ 47], a magnitude, that is, comparable to the
relative risk of schizophrenia due to obstetric complications
in general [19] or due to most genes for which an association
with schizophrenia has been observed (see [68, 69]f o r
reviews). It is remarkable that studies of RHD maternal-fetal
genotype incompatibility and schizophrenia that diﬀer in
designandpopulationcohortshouldarriveatsimilarrelative
risk estimates; this consistency suggests that the relative
risk of schizophrenia due to RHD maternal-fetal genotype
incompatibility, although small, is substantively meaningful
and worthy of more investigation.
Another way to look at the magnitude of the RHD
maternal-fetal genotype incompatibility eﬀect is to compute
the population attributable fraction, that is, the number of
cases which would not occur if the risk factor is eliminated.
Based on formulas found in [70], for RHD maternal-
fetal genotype incompatibility, the population attributable
fraction is ∼3%, as estimated from the fraction of cases
that have an RHD maternal-fetal genotype incompatibility
(7.8% [65]) and the relative risk due to the incompatibility
(using the most conservative estimate of 1.5 in [65]). Based
on a population prevalence for schizophrenia of 1% and
assuming that the allele frequencies for the RHD locus are
homogeneous in the U.S., this attributable fraction suggests
that more than 100,000 schizophrenia cases in the U.S.
would not have occurred but for the RHD maternal-fetal
genotype incompatibility. This is not a trivial number, and
forcomparison,ithasbeenestimatedthatmorethan100,000
cases of schizophrenia in the U.S. would not have occurred
but for the val allele of the COMT gene [71]. Thus, these two
loci, that is, COMT and RHD, could potentially account for
an eﬀect of similar size at the population level. Of course, the
allele frequencies at the RHD locus diﬀer across populations,
with the d allele being less common in some populations
than others (e.g., P(D) = .76 in a study conducted in
Nairobi [72]c o m p a r e dt oP(D) = .66 in the Finnish
population [73]). Thus, the frequency of Rhesus negative
mothers having Rhesus positive children will vary across
populations. This variability in allele frequencies will not
aﬀect the relative risk of disease due to RHD maternal-
fetal genotype incompatibility, but will aﬀect the fraction
of schizophrenia cases that are attributed to the RHD locus
across populations.4 Journal of Biomedicine and Biotechnology
Since most individuals who are exposed to RHD
maternal-fetal genotype incompatibility do not develop
schizophrenia, it is highly unlikely that exposure to this
adverse prenatal environment alone, that is, a phenocopy
model,explainsriskforschizophrenia.Furthermore,thelack
of evidence for violation of Hardy-Weinberg equilibrium
in the founder alleles from the family-based RHD genetic
studies [47, 67] is inconsistent with a gene-“environment”
covariation model because it suggests that mate selection
in the schizophrenia families occurred independently of
RHD genotype, at least among the founders. To date there
have been no empirical studies to determine whether the
association between RHD maternal-fetal genotype incom-
patibility and schizophrenia is explained through a gene-
“environment” interaction model.
There also is emerging evidence in studies based on
serotype data and those based on genotype data that
risk of schizophrenia due to RHD maternal-fetal genotype
incompatibility may depend on oﬀspring sex [61, 66, 67],
with a relative risk of 1.64 in male incompatible oﬀspring
and 1.07 in female incompatible oﬀspring based on a
recent meta-analysis [67]. Furthermore, a nonsigniﬁcant
trend suggesting that male oﬀspring are at higher risk than
female oﬀspring for schizophrenia due to maternal-fetal
genotype incompatibility at another RBC antigen locus,
ABO, has also been identiﬁed based on serotype data [66].
ABO maternal-fetal genotype incompatibility occurs when a
pregnant woman has type O blood and her fetus has type A
or B [48]. As with Rhesus D incompatibility, maternal IgG
antibodies can be produced against the fetal antigens and
result in hemolytic disease of the newborn [74], although in
this case the risk is the same for all pregnancies [75, 76].
These sex-dependent ﬁndings allow for hypotheses that
address why the schizophrenia eﬀect of an RBC antigen—
associated maternal immune response is so much greater for
male oﬀspring compared to female oﬀspring. It is unlikely to
be the case that RHD maternal-fetal genotype incompatibil-
ity is more likely tooccurinpregnancies withmale oﬀspring,
nor is there evidence that its related condition of hemolytic
disease of the newborn is more likely to occur in pregnancies
with male fetuses compared to female fetuses. However,
there is evidence that the clinical manifestations of RHD
maternal-fetal genotype incompatibility are more severe in
pregnancies with male fetuses than with female fetuses [77].
Thus one hypothesis is that speciﬁc schizophrenia-eﬀects
of RHD maternal-fetal genotype incompatibility (hypoxia,
hyperbilirubinemia) can aﬀect female fetuses but that they
are less likely to surpass the threshold of severity compared
to male fetuses (threshold eﬀect).
There also is evidence that the clinical eﬀects of RHD
maternal-fetal genotype incompatibility may occur earlier
in gestation for male fetuses compared to female fetuses
[77]. Coupled with research supporting sex-diﬀerences in
brain maturational rates [78], with males exhibiting a slower
pace of cerebral development compared to females [7],
another hypothesis is that male and females are equally
vulnerable to the speciﬁc eﬀects of RHD maternal-fetal
genotype incompatibility, but that these eﬀects must occur
atsex-dependenttimesduringdevelopment.Thishypothesis
further suggests that female fetuses may be at increased
risk for schizophrenia when subject to prenatal/obstetric
complications that produce hypoxia or hyperbilirubinemia,
but that these eﬀects must occur earlier in the gestational
period to increase their risk of schizophrenia (a timing
eﬀect).A third hypothesis is that male fetuses, but not female
fetuses, experience schizophrenia eﬀects due to hypoxia or
hyperbilirubinemia (a speciﬁc eﬀect). Although there have
notyetbeenstudiesaddressingwhetherriskofschizophrenia
due to RHD maternal-fetal genotype incompatibility in male
and female fetuses is a function of a threshold eﬀect or a
timingeﬀect,therehavebeenstudiesaddressingpotentialsex
diﬀerences in rates of hypoxia-related in males and females,
with conﬂicting results [79, 80].
The involvement of the RHD gene in the form of
maternal-fetal genotype incompatibility as a risk factor
for schizophrenia susceptibility is further substantiated by
analyses that showed no evidence to support the idea
that this locus is simply linked/associated with a nearby
schizophrenia susceptibility locus or that this gene acts
through the maternal genotype alone [47]. Furthermore,
there is empirical evidence consistent with the hypothe-
sized biological mechanism that previous RHD maternal-
fetal genotype incompatible pregnancies increase risk for
maternal isoimmunization in subsequent pregnancies in the
two schizophrenia—RHD maternal-fetal genotype incom-
patibility studies that tested this hypothesis [61, 65]. Using
serotype information, Hollister et al. [61] divided their
birth cohort sample into ﬁrstborn Rhesus D-incompatible
and Rhesus D-compatible males, and second- or later-born
Rhesus D-incompatible and Rhesus D-compatible males.
Consistent with a birth order eﬀect, they found the rate of
schizophrenia among the second- or later-born Rhesus D-
incompatible males was signiﬁcantly higher than the second-
orlater-bornRhesusD-compatiblemales(2.6%versus0.8%,
P = .05); but that there was no signiﬁcant diﬀerence in
the rate of schizophrenia between the ﬁrstborn Rhesus D-
incompatible and D-compatible males (P = .64).
In the second study, Kraft et al. [65] tested hypotheses
about a birth order eﬀect using nuclear families with at
least one individual with schizophrenia and RHD genotype
data. The model in which there is increased risk only to
second- or later-born incompatible children ﬁt the data
well, with a signiﬁcant point estimate of 1.7 relative risk
to second- or later-born incompatible children (P = .014).
The other model that ﬁt the data well assumed an increased
risk for all incompatible children regardless of birth order;
the point estimate for the relative risk of schizophrenia
in this model was 1.5 (lower than the former model).
However, one issue with the latter model is that it forced
the risk to ﬁrst-born incompatible children to be identical
to risk to later-born incompatible children, and essentially
produced an average relative risk across birth order groups.
Since the relative risk was estimated at 1.7 in a model
that assumed no risk to ﬁrst-born, and then the relative
risk was lowered to 1.5 in a model that averaged over all
incompatible children, the authors concluded that the eﬀect
of including the ﬁrst-born incompatible children was to
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RHD maternal-fetal genotype incompatibility for the later-
born children. It is important to note that neither study had
information on pregnancies that did not go to full term, for
example, spontaneous abortions. The potential eﬀect of this
lack of information is to misclassify some RHD maternal-
fetal genotype incompatible individuals as ﬁrst-born (and
at very low risk from maternal sensitization) when in fact
they were later-born and at heightened risk due to previous
maternal sensitization. Such misclassiﬁcation would serve
to underestimate the diﬀerence between groups and bias
results toward the null hypothesis of no birth order eﬀect.
In light of the challenges of truly examining a birth order
eﬀect with RHD maternal-fetal genotype incompatibility, it
is striking that the two schizophrenia studies that chose to
testbirthorderhypothesesfoundevidenceinsupportofsuch
an eﬀect. However, further examination of this hypothesis is
warranted due to the ﬁndings that suggest that the risk of
schizophrenia associated with RHD maternal-fetal genotype
incompatibility is limited to male oﬀspring. In this case, one
would expect to observe an increased risk among second-
or later-born incompatible males, but not females. This
hypothesis has not yet been tested.
The involvement of Rhesus D incompatibility in
schizophrenia was initially provided by studies that inferred
genotype status through serotype data. Importantly, the evi-
dence from these non-genetic studies provided the impetus
for conceptualizing maternal-fetal genotype incompatibility
as a more general non-Mendelian mechanism involved in
the etiology of complex disorders such as schizophrenia.
The ﬁrst candidate gene study to test the hypothesis of
RHD maternal-fetal genotype incompatibility as a risk factor
for schizophrenia [47] provided the proof of principle that
this non-Mendelian mechanism can be tested with genotype
data. Further, it facilitated the development of statistical
methods and study designs based on a candidate gene
approach and nuclear families for addressing hypotheses
about the role of maternal-fetal genotype incompatibility in
disease[65,81–85].Suchinnovationsareimportantbecause,
as illustrated in the next section, not all “incompatibility
genes” can be inferred through serotype data.
3.HLA-B Maternal-FetalGenotype
Incompatibility as a Risk Factor for
Schizophrenia: When MaternalandFetal
GenotypesDo Not Differ
Human leukocyte antigens (HLAs) play an important role
in the control of immune responses [86] and there has
long been a belief that HLAs play a role in schizophrenia
susceptibility, although with conﬂicting results from genetic
studies examining the hypothesis of a high risk allele acting
through the aﬀected individual’s genotype [87]. Another
way to conceptualize the role of HLA in schizophrenia
susceptibility is to consider its role(s) in pregnancy. There
is strong evidence for maternal recognition of paternally-
derived fetal HLAs during pregnancy because maternal
antibodies against these fetal antigens have been detected
[88]. However, maternal recognition of paternally-derived
fetal HLAs that diﬀer from maternal HLAs is believed to
be beneﬁcial to implantation and maintenance of pregnancy
because maternal antibodies to fetal antigens have been
observed in a large number of healthy pregnancies. In
contrast, lack of maternal recognition, which is the result of
paternally derived HLAs that are not perceived as diﬀerent
from the maternal HLAs, may lead to adverse reproductive
outcomes [88].
The underlying biological mechanism for poor repro-
ductive outcomes is not yet known, however, an immuno-
logical intolerance hypothesis posits that HLA similarity
between mother and fetus fails to stimulate an adequate
maternal immune response that is necessary for proper
implantation and maintenance of pregnancy [89]. There
is some empirical evidence that situations where maternal
sensitization would not occur, that is, HLA matching
between couples or between mother and fetus, increases the
risk of fetal loss [89–92], preeclampsia [93–96], low birth
weight [97–100], newborn encephalopathy, and seizures
[101]. Importantly, low birth weight and preeclampsia are
complications that have been associated with schizophrenia
[15, 19, 102–104]. The mechanism(s) by which low birth
weight or preeclampsia increase risk for schizophrenia is not
yet known. However, a current theory regarding preeclamp-
sia hypothesizes that this condition gives rise to abnormal
fetal blood ﬂow that results in chronic fetal hypoxia or mal-
nutrition [105] and both of these conditions are associated
with schizophrenia [15, 16, 28–31, 102, 103]. Furthermore,
preeclampsia involves a generalized inﬂammatory response
inthemotherasaresultoftheoxidativelystressedorhypoxic
placenta[106],andinﬂammatoryprocessesarehypothesized
to damage the microvasular system of the brain [43, 44]a n d
increase risk of schizophrenia [43].
Two additional lines of evidence implicate maternal-fetal
HLA matching in schizophrenia. First, evidence supporting
the relevance of HLA matching to neurodevelopmental
disorders comes from a study that found that parents of
children with autism were signiﬁcantly more likely to share
at least one HLA-A, -B,o r-C a n t i g e ni nc o m m o nc o m p a r e d
with parents of unaﬀected children [107]. Second, circum-
stantial evidence supporting the relevance of HLA matching
speciﬁcally to schizophrenia comes from the literature on
mate selection and the literature on olfaction in schizophre-
nia. Speciﬁcally, in the mate selection literature there is
some evidence to support disassortative mate selection with
respect to HLA loci [108–111] and that olfaction plays a
role in this process [109, 110, 112]. However, studies of
individuals with schizophrenia and their unaﬀected ﬁrst
degree relatives reveal impairments in olfaction [113–116].
Hence, mate selection in this subgroup of individuals may be
less likely to be guided by the ability to “sniﬀ out” a mate
with HLA dissimilarity, and thus more likely to result in
the construction of couples with HLA similarity for whom
maternal-fetal HLA matching is more likely to occur.
Because risk of schizophrenia is associated with pre-
natal/obstetric complications, including preeclampsia and
low birth weight, maternal-fetal HLA matching has been
associated with these and other pregnancy/obstetric com-
plications, maternal-fetal HLA matching has been observed6 Journal of Biomedicine and Biotechnology
in another neurodevelopmental disorder, and maternal-
fetal HLA matching may occur more frequently in families
of individuals with schizophrenia for biological reasons, a
candidate gene study was conducted to assess maternal-fetal
genotype incompatibility, that is, matching, at the HLA-
A, -B,a n d-DRB1 loci as a risk factor of schizophrenia
[117]. For this study, Palmer and colleagues hypothesized
that maternal-fetal genotype incompatibility increased risk
of schizophrenia through a general allele-matching phe-
nomenon rather than through speciﬁc allele combinations.
F o re a c hl o c u s ,m o t h e ra n do ﬀspring were considered to
match if the oﬀspring’s alleles were identical to the maternal
allelesoriftheoﬀspring’salleleswereasubsetofthematernal
alleles. In either of these cases, maternal sensitization to fetal
antigens would not occur because they would be perceived
to be the same as the maternal antigens. The maternal-fetal
genotype incompatibility test for multiple siblings [65]w a s
modiﬁedtoaccommodateanalysesinvolvingageneralallele-
matchingphenomenonandmissingparentalgenotypes[82].
There was no evidence for violation of Hardy-Weinberg
equilibrium in the founder alleles, consistent with random
mating with respect to these three loci. There was no
evidence for HLA-A or -DRB1 maternal-fetal genotype
matching eﬀect on schizophrenia. In contrast, there was
signiﬁcant evidence for an HLA-B maternal-fetal genotype
incompatibility eﬀect (P = .01) where inspection of the
parameter estimates revealed that maternal-fetal genotype
matching produced a higher risk for female oﬀspring (1.74,
95% CI: 1.22–2.49) than for male oﬀspring (1.11, 95% CI:
0.76–1.61). Of note, in the mate selection literature, HLA-B
appears to be particularly inﬂuential [118].
As this is the ﬁrst study to demonstrate an association
between HLA-B matching and schizophrenia, much more
research is needed to determine the mechanism through
which this form of maternal-fetal genotype incompatibility
increases risk for schizophrenia. One possibility is that HLA-
B matching increases risk for adverse reproductive outcomes
such as preeclampsia or low birth weight. This hypothesis
could be tested by examining prenatal and birth records in
a sample of females with schizophrenia stratiﬁed by HLA-B
matching status, and comparing the rates of preeclampsia,
low birth weight, and other pregnancy/obstetric complica-
tions between the two groups. It also currently is unclear
why female oﬀs p r i n gw o u l db em o r ev u l n e r a b l et oe ﬀects
of HLA-B matching than male oﬀspring. One possibility is
that female fetuses are more likely to survive the putative
eﬀects of HLA-B matching, such as preeclampsia [119]
and hence to be observed in a study, than male oﬀspring.
Although the sex-dependent ﬁnding is intriguing in light of
the work demonstrating that RHD maternal-fetal genotype
incompatibility as a schizophrenia risk factor is limited to
males [67], replication and investigation of hypothesized
clinicalmanifestationsofHLA-Bmatching(lowbirthweight,
preeclampsia, other complications) are warranted because
other published studies reveal conﬂicting results regard-
ing sex diﬀerences in the rates of low birth weight and
preeclampsia among individuals with schizophrenia [102,
104]. Because the ﬁrstborn child of a couple is at highest
risk for preeclampsia, one could also seek further evidence in
support of an HLA-B matching—preeclampsia relationship
by testing for a birth order eﬀect.
Future research must provide additional evidence for
an association between HLA-B matching and schizophrenia,
determine if there are clinical outcomes of HLA-B matching,
forexample,prenatal/obstetriccomplications,whetherHLA-
B matching increases risk through a phenocopy model
or a gene-“environment” interaction model, or is simply
associatedthroughagene-“environment”covariationmodel,
and determine the basis for a sex-dependent risk. It will
be particularly important to distinguish between a gene-
“environment”covariationmodelandagene-“environment”
interaction model given the a priori basis for expecting
higher rates of HLA-B matching in schizophrenia as a
function of olfaction deﬁcits.
4.FutureResearch
Based on this review, there are a variety of hypotheses that
could be tested in future research to further elucidate the role
of RHD and HLA-B maternal-fetal genotype incompatibility
in schizophrenia. One important area of research would
focus on conducting studies that add to the evidence
that these maternal-fetal genotype incompatibilities are
risk factors for schizophrenia. As examples, since RHD
maternal-fetal genotype incompatibility is genetic in origin,
one would expect more clustering of schizophrenia in
families with RHD maternal-fetal genotype incompatibility
than in schizophrenia families without RHD maternal-fetal
genotype incompatibility. The same hypothesis holds for
HLA-B maternal-fetal genotype incompatibility. If RHD
maternal-fetal genotype incompatibility is a risk factor
speciﬁcally for males, one would expect to observe that
schizophrenia risk is associated with a birth order eﬀect with
male oﬀspring exposed to RHD maternal-fetal genotype
incompatibility, but not for female oﬀspring. If HLA-B
matching is involved in predisposition to pre-eclampsia,
low birth weight, or other prenatal/obstetric complication,
one would expect higher rates of these prenatal/obstetric
complications in individuals with schizophrenia with HLA-
B maternal-fetal genotype matching compared to those
without HLA-B maternal-fetal genotype matching. If HLA-B
matching is involved speciﬁcally in predisposition to pre-
eclampsia, one would expect to observe that schizophrenia
risk is associated with a birth order eﬀect with female oﬀ-
spring exposed to HLA-B maternal-fetal genotype incom-
patibility, but not for male oﬀspring.
A second area of research would focus on if/how the ma-
ternal-fetal genotype incompatibility integrates with genetic
liability for schizophrenia (phenocopy, gene-environment
covariation,andgene-environmentinteraction).Thepheno-
copy and gene-environment covariation models are unlikely
to explain the association between RHD maternal-fetal
genotype incompatibility and schizophrenia. However, one
possible explanation for the ﬁnding that most people with
a history of Rhesus D incompatibility do not develop
schizophrenia is that the schizophrenia-producing eﬀect of
RHDmaternal-fetalgenotypeincompatibility manifestsonly
in individuals with genetic predisposition to schizophrenia.Journal of Biomedicine and Biotechnology 7
This is a gene-“environment” interaction hypothesis. If
this is the case, then one would expect diﬀerent risks
for schizophrenia based on family history and RHD
maternal-fetal genotype incompatibility, with greatest risk
of schizophrenia among genetically high risk individuals
who are exposed to RHD maternal-fetal genotype incom-
patibility. Following the recent work of Clarke et al. [27],
one could test for synergism between RHD maternal-fetal
genotype incompatibility and family history of psychosis by
comparing the rates of schizophrenia across four groups:
no RHD maternal-fetal genotype incompatibility and no
family history of psychosis, RHD maternal-fetal genotype
only, family history of psychosis only, and RHD maternal-
fetal genotype incompatibility and positive family history of
psychosis. The same interaction hypothesis could be tested
for HLA-B maternal-fetal genotype incompatibility; however
additional research is needed also to test the phenocopy and
gene-environment covariation models with respect to the
association between HLA-B matching and schizophrenia.
A third area of research would focus on hypotheses that
hypoxia is the prominent schizophrenia-producing eﬀect
of RHD/HLA-B maternal-fetal genotype incompatibility. As
examples, if the schizophrenia risk eﬀect of RHD maternal-
fetal genotype incompatibility is the result of hypoxia,
then one would expect to observe an interaction between
RHD maternal-fetal genotype incompatibility and hypoxia-
regulated/vascular-expression genes. The same hypothesis
can be tested with HLA-B maternal-fetal genotype incom-
patibility. If the schizophrenia risk eﬀect of RHD maternal-
fetal genotype incompatibility is the result of hypoxia,
then one would expect to observe smaller hippocampal
volume in individuals with schizophrenia exposed to RHD
maternal-fetal genotype incompatibility compared to those
not exposed. The same hypothesis can be tested with HLA-B
maternal-fetalgenotypeincompatibility. Iftheschizophrenia
risk eﬀect of RHD maternal-fetal genotype incompatibility
is the result of hypoxia, then one would expect RHD
maternal-fetal genotype incompatibility to be associated
with neurocognitive functions that may be sensitive to the
eﬀects of prenatal hypoxia in schizophrenia, for example,
verbal learning and memory. The same hypothesis can be
tested with HLA-B maternal-fetal genotype incompatibility.
A fourth area of research would focus on hypotheses
to further examine oﬀspring sex-dependent diﬀerences in
the schizophrenia-producing eﬀects of RHD maternal-fetal
genotype incompatibility. For this area of research, hypothe-
ses regarding sex-dependent diﬀerences in amount of expo-
sure (threshold eﬀect), gestational timing of exposure (tim-
ing eﬀect), and type of exposure, that is, hypoxia and hyper-
bilirubinemia (speciﬁc eﬀect) are likely best tested using
animal models which can systematically vary conditions of
hypoxia and hyperbilirubinemia. Similar investigations can
be performed when the prenatal eﬀects of HLA-B maternal-
fetal genotype incompatibility are better elucidated.
A ﬁfth area of research would focus on identifying other
“incompatibility”genes.Theattributableriskassociatedwith
these maternal-fetal genotype incompatibilities is limited to
populations in which the incompatibility occurs with appre-
ciable frequency. As one example, the Rhesus D negative
allele is less common in African and Asian populations than
European Caucasian populations [72, 120, 121], hence RHD
maternal-fetal genotype incompatibility is less likely to con-
tribute to schizophrenia susceptibility in those populations.
However, RHD is not the only blood antigen locus for which
a maternal-fetal genotype incompatibility could arise. Other
blood antigens exist, including ABO [48], RHCE [122], Kell
[123, 124], Duﬀy[ 125], Kidd [48], and MN [125, 126]a n d
maternal-fetal genotype incompatibilities for these antigens
can give rise to a maternal immune response that is similar,
although smaller in magnitude, to the RHD incompatibility
response. In addition, other genes that could lead to fetal
hypoxia, hyperbilirubinemia, or other prenatal conditions
associated with schizophrenia, whether through maternal-
fetalgenotypeincompatibility,maternalgeneticeﬀectsalone,
or fetal genetic eﬀects alone, should be examined.
5. Conclusion
Prenatal environmental factors are quite heterogeneous and
diﬃcult to document reliably, making it diﬃcult to test
the role of environmental insults in the pathogenesis of
schizophrenia. However, there is growing evidence that
many prenatal/obstetric complications have a genetic basis,
and one stream of research has focused on identifying
combinations of maternal-fetal genotypes, that is, maternal-
fetal genotype incompatibilities, that predispose to prena-
tal/obstetric complications. Maternal-fetal genotype incom-
patibilitycanoccurwhenmaternalandfetalgenotypesdiﬀer,
for example, RHD maternal-fetal genotype incompatibility,
or when they are too similar, for example, HLA-B maternal-
fetal genotype incompatibility. Thus far, the RHD, ABO,
and HLA-B g e n e sh a v eb e e ni m p l i c a t e da sr i s kf a c t o r s
for schizophrenia, with increasing evidence that male and
female oﬀspring may be diﬀerentially vulnerable to the
eﬀects of maternal-fetal genotype combinations involving
these genes. A growing number of studies demonstrate that
an interaction between prenatal/obstetric complications and
putative susceptibility genes increases risk for schizophrenia.
Thus, these maternal-fetal genotype incompatibilities are
likely to be part of a complex mixture of factors (genetic
and environmental), which together act on the brain in ways
yet to be identiﬁed to result in schizophrenia. The empiric
data demonstrating a relationship between these maternal-
fetal genotype incompatibilities and schizophrenia provide
hypotheses for future investigations to further our under-
standing of their role in increasing risk of schizophrenia.
Untilrecently,studiestounderstandtheroleofmaternal-
fetal genotype incompatibility in schizophrenia (or any
complex disorder) have inferred immunologically relevant
genotypes solely from birth records and for the single
phenomenon of hemolytic disease. As illustrated in this
review, maternal-fetal genotype incompatibility at other loci,
such as HLA loci, may also increase risk for schizophrenia.
However, because these loci do not result in hemolytic
disease of the newborn it may be challenging, a priori,
to examine their role through information gleaned from
birth records. Hence, the development of study designs and
statistical methods to study prenatal risk factors based on8 Journal of Biomedicine and Biotechnology
genotype data are essential for further delineating maternal-
fetal genotype incompatibility as a non-Mendelian mecha-
nism in complex disease. In fact, genetic studies that do not
model non-Mendelian patterns of inheritance directly may
be one contributing reason that current genome scans have
not found striking and highly replicable results in complex
disorders that otherwise are so highly familial.
The approach described here integrates the investigation
of genes and environment in an innovative manner and
provides empirical data that ﬁts within and can be further
tested in a genetic-inﬂammatory-vascular hypothesis of
schizophrenia. There are several reasons why it is important
to further investigate maternal-fetal genotype incompatibly
as a risk factor for schizophrenia: (1) it is a new research
approach that allows precise identiﬁcation of a putative
high-risk prenatal environment, even years after the adverse
environment has occurred; (2) using a genetic approach, it is
possible to simultaneously evaluate alternative explanations
of allelic eﬀects that act solely through the genotype of
the mother or child; (3) if certain maternal-fetal genotype
incompatibilities, for example, RHD, do increase risk for
schizophrenia, then eﬀorts could be launched to increase
prevention of the eﬀects of this class of risk factor; (4) this
approach could serve as a model for studying other complex
disorders for which maternal-fetal genotype incompatibili-
ties may be involved, for example, diabetes [127, 128]a n d
rheumatoid arthritis [129–131].
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